American Society of Hirudotherapy

Livedoid Vasculopathy (Investigational Adjunct)

Investigational adjunct for livedoid vasculopathy; no clinical leech study was identified, and anticoagulation and IVIG remain guideline first-line.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 10, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for livedoid vasculopathy. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational and is in most patients precluded by concurrent systemic anticoagulation.
What evidence exists?
Tier C (investigational). No clinical study of leech therapy for livedoid vasculopathy was identified in our literature search; a German S1 guideline lists leeches among options without a clear recommendation. The disease is a thrombo-occlusive disorder of dermal microvessels producing painful purpuric macules, ulcers, and atrophie blanche scars, predominantly on the lower legs, and is associated with thrombophilic states (factor V Leiden, prothrombin mutation, antiphospholipid syndrome, hyperhomocysteinemia, MTHFR variants), although in many studies a known prothrombotic abnormality is found in fewer than half of patients; a targeted workup is still advised. Care is off-label and guided by expert consensus: German guidance places low-molecular-weight heparin, direct oral anticoagulants such as rivaroxaban, and intravenous immunoglobulin first-line (immunoglobulin is effective but costly), with warfarin or phenprocoumon and iloprost second-line; hyperbaric oxygen rests on single-case reports.
Main risks
  • Severe and prolonged bleeding from bite sites, especially if concurrent anticoagulation is not held
  • Worsening of ulcer formation if a leech is placed on or adjacent to a vasculopathic lesion
  • Non-healing bite wound, since underlying microvascular disease impairs healing
  • Local skin infection or Aeromonas infection
  • Allergic reaction to leech saliva
  • Delay of systemic anticoagulation, hyperbaric oxygen, or IVIG, all of which are evidence-supported
  • Compounding of bleeding risk in patients with antiphospholipid syndrome already at thrombosis-bleeding balance
Who should not consider this
  • Patients on systemic anticoagulation (warfarin, DOACs, heparin) — this is the great majority of livedoid vasculopathy patients
  • Patients with active ulceration at the proposed placement site
  • Patients without a completed thrombophilia workup
  • Pregnant patients (livedoid vasculopathy is associated with antiphospholipid syndrome)
  • Patients with recent thrombotic event
  • Patients with anemia
What to ask your clinician
  • Has my thrombophilia workup been completed, including factor V Leiden, prothrombin mutation, antiphospholipid antibodies, homocysteine, and MTHFR?
  • Am I on antiplatelet therapy and anticoagulation, and has the regimen been optimized?
  • Has hyperbaric oxygen or IVIG been considered for my refractory disease?
  • If I am on anticoagulants, can they be safely held for leech therapy, and what is the hematology plan?
  • Where exactly will the leech be placed — confirm it is on intact skin adjacent to, not on, any lesion?
  • What is the realistic expected benefit, and what is the risk of compounding bleeding?
When to seek urgent care
  • Bleeding from a bite site that soaks through more than one dressing per hour, or any bleeding lasting more than 24 hours
  • New ulceration or worsening of an existing ulcer
  • Spreading redness, warmth, pus, or red streaks around any bite site or lesion
  • Fever above 38.0 C / 100.4 F or chills
  • New leg swelling, redness, or tenderness (DVT concern)
  • Sudden shortness of breath or chest pain (pulmonary embolism)

What this does NOT mean

  • It does not substitute for systemic anticoagulation, which is the cornerstone of therapy when not contraindicated.
  • It does not address the underlying thrombophilia, which must be identified and managed by hematology.
  • Most patients with livedoid vasculopathy are on anticoagulation, which itself is an absolute contraindication to leech therapy.
  • No clinical study of leech therapy for livedoid vasculopathy was identified, and a German S1 guideline gives it no clear recommendation; the risk of additive bleeding makes routine use unsafe.

Clinical Profile

Category
Vascular
ICD-10
L95.0, I77.6
Safety tier
High

Evidence Summary

Livedoid vasculopathy is a chronic thrombo-occlusive disorder of dermal microvessels producing painful purpuric macules, ulcerations, and atrophie blanche scars, predominantly on the lower extremities. It is associated with thrombophilic states (factor V Leiden, prothrombin mutation, antiphospholipid syndrome, hyperhomocysteinemia, MTHFR variants) which must be worked up. All treatments are off-label, and the German S1 guideline (AWMF 013-098, 2025) ranks them by expert consensus: low-molecular-weight heparin, direct oral anticoagulants (for example rivaroxaban) and intravenous immunoglobulin first-line (IVIG usually after the other first-line options because of cost); iloprost, vitamin B6/B12/folate for hyperhomocysteinemia and warfarin or phenprocoumon second-line; and NSAIDs, glucocorticoids, fibrinolytics, hyperbaric oxygen (single-case reports), PUVA, danazol and leeches without a clear recommendation. Antiplatelet drugs (aspirin, dipyridamole) and pentoxifylline are described as further options in a 2022 review (Front Med, doi 10.3389/fmed.2022.1012178), and identified thrombophilia is treated. No clinical study of leech therapy for livedoid vasculopathy (case report, case series or trial) was identified in PubMed, Europe PMC, OpenAlex or ClinicalTrials.gov, or in Russian- and German-language sources (searched October 2026). The German S1 guideline names leeches only in its list of options without a clear recommendation and has no text section on them. The mechanistic rationale of leech-saliva anticoagulant proteins is untested in this indication, and most patients are already on systemic anticoagulation that is itself a contraindication.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Active deep vein thrombosis (acute phase)
  • Critical limb ischemia (ABI <0.4)
  • Concurrent systemic anticoagulation (most patients) — coordinate with hematology
  • Active ulceration at placement site (absolute)
  • Untreated thrombophilia workup
  • Pregnancy (livedoid vasculopathy is associated with antiphospholipid syndrome)
  • Recent thrombotic event

Related ASH Compounds

Synthetic drugs mentioned for this condition. They act on the same targets as leech molecules but are not derived from the leech:

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.